Ontology highlight
ABSTRACT:
SUBMITTER: Butters O
PROVIDER: S-EPMC6647870 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Butters Oliver O Young Kate K Cunningham David D Chau Ian I Starling Naureen N
Frontiers in oncology 20190716
In 2014, the survival benefits seen in REGARD and RAINBOW studies led the way for the regulatory approval of ramucirumab in the second line setting in oesophagogastric (OG) cancer. Trials of other drugs targeting the vascular endothelial growth factor (VEGF) pathway have met with mixed results but this remains an important pathway for evaluation in OG cancer. Perhaps the most interesting ongoing trials are those which target VEGF in combination with immunotherapy, which have a sound scientific r ...[more]